Drug Trial Radar · NCT07557914
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Jan 21, 2026
Primary completion
Dec 2029
Study completion Dec 2030
Sponsor
- Lead sponsor
- Haibo ShaoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- First Hospital of China Medical University; Liaoning Cancer Hospital & Institute; The General Hospital of Northern Theater Command; The Affiliated Hospital of Yanbian University; Harbin Medical University Third Affiliated Hospital
- First posted
- Apr 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.
Conditions
- HCC - Hepatocellular Carcinoma
- Diabetes
Interventions
EpalrestatDrug
For the first 6 patients in the safety lead-in period, the starting dose of epalrestat was 50 mg, three times per day. If dose-limiting toxicity (DLT) occurred in the first 6 patients, the dose for the second round of 6 patients in the safety lead-in period would be adjusted to 50 mg, twice per day. If DLT occurred in the second round of 6 patients, the dose for the third round of 6 patients in the safety lead-in period would be adjusted to 50 mg, once per day.
Donafenib + TislelizumabDrug
donafenib 0.2g BID, tislelizumab 200mg/21days
HAICProcedure
Include FOLFOX and RALOX.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 12-month Event-free survival (EFS) RateTime frame: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Yanbian University Hospital
Yanji, Jilin, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Active not recruiting
Liaoning Cancer Hospital
Shenyang, Liaoning, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.